Drug Patents owned by Dermavant Sci

1. List of Vtama drug patents

VTAMA's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10647649 DERMAVANT SCI Process for preparing tapinarof
Nov, 2038

(15 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10426743 DERMAVANT SCI Topical pharmaceutical compositions
May, 2036

(13 years from now)

US11458108 DERMAVANT SCI NA
May, 2036

(13 years from now)

US10195160 DERMAVANT SCI Topical pharmaceutical compositions
May, 2036

(13 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 23, 2027

Drugs and Companies using TAPINAROF ingredient

NCE-1 date: 2026-05-23

Market Authorisation Date: 23 May, 2022

Treatment: Topical treatment of plaque psoriasis in adults

Dosage: CREAM;TOPICAL

More Information on Dosage

VTAMA family patents

14

United States

6

Japan

3

China

3

Israel

3

Australia

3

European Union

2

Singapore

2

Brazil

2

Colombia

2

Mexico

2

Korea, Republic of

2

Canada

2

Chile

1

Portugal

1

Uruguay

1

Russia

1

Spain

1

Jordan

1

Croatia

1

Costa Rica

1

IB

1

Dominican Republic

1

Philippines

1

Argentina

1

Morocco

1

Peru

1

Taiwan, Province of China

1

Hong Kong

1

EA

1

South Africa

1

Lithuania

1

Hungary

1

Slovenia

1

Ukraine

1

Poland

1

RS

1

Denmark

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic